Keryx Biopharmaceuticals Announces Issuance Of U.S. Patent For Zerenex™ Covering Orally Administrable Forms Of Ferric Citrate
Published: Dec 18, 2013
NEW YORK, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,609,896. The patent, which expires in 2024, claims orally administrable forms of Zerenex prepared from ferric citrate having a BET active surface area greater than about 16 sq. m/g. The active pharmaceutical ingredient (API) of Zerenex is ferric citrate having a BET surface area substantially above this surface area threshold.
Help employers find you! Check out all the jobs and post your resume.